First Patient Dosed in Phase I/IIa Study of DualityBio’s BDCA2-Targeting ADC DB-2304 for Systemic Lupus Erythematosus

Fast Track Designation Granted for AVZO-1418/DB-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN

Invitation Letter | 2025 DualityBio R&D Day

DualityBio’s ADAM9-Targeting ADC DB-1317 Receives FDA IND Clearance, Global Clinical Trials Initiated Simultaneously

DualityBio and BioNTech Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer